You are here: Industry Insights > Omicron

News List

COVID-19 vaccines may be less effective against Omicron, says WHO expresspharma
December 17, 2021
The WHO, in its weekly epidemiological update, said that more data was needed to better understand the extent to which Omicron may evade immunity derived from either vaccines or previous infection.
Study finds Omicron multiplies 70 times faster than Delta, UK COVID-19 cases exceed 75,000 PharmaTimes
December 17, 2021
A warning has been issued to UK MPs from the head of NHS England that hospitalisations could exceed numbers recorded in January 2021.
Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron AmericanPharmaceuticalReview
December 17, 2021
Vaxart, Inc. plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the Omicron SARS-CoV-2 variant in two different studies expected to begin next month.
Vaccines still provide ‘significant protection’ against severe COVID-19 PharmaTimes
December 16, 2021
Omicron has been the latest variant to test the effectiveness of COVID-19 vaccines.
CDC Warns of Coming Omicron Wave Drugs
December 16, 2021
The omicron variant is spreading rapidly in the United States and could trigger a huge wave of COVID-19 infections as early as January, federal health officials said Tuesday.
Covid-19: Pfizer’s antiviral Paxlovid effective against severe disease and Omicron variant Pharmaceutical-Technology
December 16, 2021
Pfizer has announced that its investigational Covid-19 antiviral, Paxlovid, offers high protection against severe disease from coronavirus and is effective against the new variant Omicron.
Omicron Resists Pfizer Vaccine but Causes Less Severe Disease Drugs
December 15, 2021
Compared with previous coronavirus variants, omicron appears to cause less severe illness, but is more resistant to the Pfizer vaccine, researchers at South Africa's largest health insurer report.
British Study Shows Vaccines Weaken Against Omicron, but Boosters Help Drugs
December 14, 2021
The ability of two-dose COVID-19 vaccines to protect against symptomatic infection by the omicron variant falls significantly short, but a booster shot provides considerable protection...
Brii Bio’s tests show combo therapy retains activity against Omicron Pharmaceutical-Technology
December 14, 2021
Brii Biosciences has reported that its combination therapy of non-competing Covid-19 monoclonal antibodies (mAb), amubarvimab and romlusevimab (BRII-196/BRII-198)...
Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant prnasia
December 13, 2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens...

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page